DEFA14A: Precipio Urges Shareholders to Vote Immediately to Avoid Costly Meeting Rescheduling

Precipio, Inc. is requesting shareholders to vote their shares by 11 p.m. Eastern Time on June 12th to ensure quorum for the annual shareholders meeting and avoid potential rescheduling costs of up to $100,000.

Summary

• Precipio, Inc., a specialty cancer diagnostics company, is urging its shareholders to vote their shares immediately to ensure a quorum for the upcoming shareholders meeting scheduled for June 13, 2024.
• As of June 12, 2024, approximately 44% of shares have been voted, and a minimum of 50% is required to hold the meeting.
• If the meeting is adjourned due to insufficient votes, the company estimates that rescheduling costs could reach $100,000, which includes expenses for a proxy solicitor, legal fees, and administrative costs.
• The current cost of the shareholder meeting is less than $5,000.
• Management emphasizes that all shareholders should vote by 11 p.m. Eastern Time on June 12th, regardless of whether they vote for or against, to meet the quorum requirement and avoid unnecessary expenses.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the company is facing a potential issue with shareholder voting, they are actively addressing it. The risk of incurring additional costs is a concern, but the company's proactive approach mitigates some of the negativity.

Positives

• The company is proactively addressing a potential issue with shareholder voting to avoid unnecessary costs.
• The current cost of the shareholder meeting is relatively low at less than $5,000.

Negatives

• The company has not yet achieved the required 50% quorum for the shareholder meeting.
• Rescheduling the meeting could result in significant costs of up to $100,000.

Risks

• Failure to achieve quorum could lead to a costly adjournment and rescheduling of the annual shareholders meeting.
• The company's reliance on shareholder participation introduces uncertainty into the meeting's outcome.

Future Outlook

The company is focused on ensuring a quorum for the upcoming shareholder meeting to avoid unnecessary costs. Forward-looking statements are subject to risks and uncertainties as detailed in SEC filings.

Management Comments

• Management is requesting that shareholders instruct their brokers to vote their shares immediately.
• Management would like to avoid these unnecessary expenditures.

Industry Context

In the biotechnology industry, shareholder meetings are crucial for corporate governance and strategic decision-making. Ensuring adequate shareholder participation is a common challenge, and companies often employ proxy solicitation firms to encourage voting.

Comparison to Industry Standards

• Proxy solicitation costs can vary widely depending on the size and complexity of the company and the issues being voted on.
• For smaller companies like Precipio, proxy solicitation costs can range from $20,000 to $100,000 or more if a significant effort is required to achieve quorum.
• Larger companies may spend significantly more, sometimes exceeding $1 million, on proxy solicitation efforts.
• Companies like Exact Sciences and Guardant Health, which are larger players in the cancer diagnostics space, likely have more robust shareholder engagement programs and potentially lower relative costs for ensuring quorum.

Stakeholder Impact

• Shareholders may be impacted by potential costs associated with rescheduling the meeting.
• The company's ability to execute its strategic goals could be affected if the shareholder meeting is delayed.

Next Steps

• Shareholders need to vote by 11 p.m. Eastern Time on June 12, 2024.
• The shareholders meeting is scheduled for June 13, 2024, at 10 a.m. Eastern Time.

Key Dates

Keywords

shareholders meeting, proxy vote, quorum, Precipio, PRPO, cancer diagnostics, rescheduling costs